title: Single-dose treatment for paucibacillary leprosy; clinical problems and management.
authors.forename: V V
authors.initials: VV
authors.lastname: Pai
authors.forename: H O
authors.initials: HO
authors.lastname: Bulchand
authors.forename: C R
authors.initials: CR
authors.lastname: Revankar
authors.forename: R
authors.initials: R
authors.lastname: Ganapati
mesh_terms: D000293:Adolescent; D000900:Anti-Bacterial Agents / Q000008:administration & dosage / Q000627:therapeutic use; D000890:Anti-Infective Agents / Q000008:administration & dosage / Q000627:therapeutic use; D002648:Child; D002991:Clofazimine / Q000627:therapeutic use; D004359:Drug Therapy, Combination; D006801:Humans; D007917:Leprostatic Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D007918:Leprosy / Q000188:drug therapy* / Q000382:microbiology / Q000517:prevention & control; D008911:Minocycline / Q000008:administration & dosage / Q000627:therapeutic use; D009166:Mycobacterium leprae / Q000187:drug effects*; D015242:Ofloxacin / Q000008:administration & dosage / Q000627:therapeutic use; D011239:Prednisolone / Q000627:therapeutic use; D012293:Rifampin / Q000008:administration & dosage / Q000627:therapeutic use; D055502:Secondary Prevention
chemical_list: D000900:Anti-Bacterial Agents; D000890:Anti-Infective Agents; D007917:Leprostatic Agents; D011239:Prednisolone; D015242:Ofloxacin; D002991:Clofazimine; D008911:Minocycline; D012293:Rifampin